3rd Quarter - Report
W STRATEGIES, LLC for GENZYME CORPORATION
Firm
Client
Income
$30,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Monitoring the implementation of the Patient Protection and Affordable Care Act, including provisions related to a regulatory pathway for biosimilars, and provisions related to orphan drugs. Monitored deficit reduction initiatives related to enactment of an increase in the U.S. federal debt ceiling. P.L. 112-25 - The Budget Control Act of 2011.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Medicare/Medicaid MMM
P.L. 112-25 - The Budget Control Act of 2011 as it relates to Medicare reimbursement for Part B drugs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.